Navigation Links
BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
Date:1/8/2014

s approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium). Auxilium is partnered with Actelion Pharmaceuticals Ltd. for the marketing of XIAFLEX in Canada and Australia, and Swedish Orphan Biovitrium AB for the marketing of XIAPEX® (the EU tradename for CCH) in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome in a Phase 2b study and also for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas. For more information, please visit www.biospecifics.com.

Forward-Looking Statements
This release includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements." The forward-looking statements include statements concerning, among other things, the design and timing of future studies to access the efficacy and safety of CCH for the treatment of human lipoma or their likelihood of success; the potential of CCH for the treatment of human lipomas by comparison with surgery; whether Auxilium will exercise its opt-in rights for human lipoma following the completion of a new trial; and the development of CCH for other
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
11. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) ... financial results after the market closes on Tuesday, August ... will be held on Tuesday, August 4, 2015, at ... To participate in the call, please dial 877-303-1298 ... rebroadcast of the teleconference will be available for one ...
(Date:7/28/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/cng4gn/refurbished ) ... Equipment Market - Global Forecasts to 2019" report ... equipment market is estimated to grow expected to reach ... from 2014 to 2019. Factors ... to financial constraints, increasing privatization in the healthcare sector, ...
(Date:7/28/2015)...  PD-Rx Pharmaceuticals, Inc., a publicly held corporation, ... with Dobson Technologies, a fully-integrated outsourced IT provider, ... PD-Rx is an Application Service Provider ... Using Dobson Technologies, IaaS solution will allow PD-Rx ... regulatory compliance, and reduce operating expenses.  "The most ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce Second Quarter 2015 Financial Results 2Refurbished Medical Equipment Market 2015 - Global Forecasts to 2019 2PD-Rx Partners With Dobson Technologies 2
... Theramed Corporation ("Theramed") announces that it will ... of the Society of Obstetricians and Gynecologists of Canada. ... used to advance the practice of obstetrics, from Glenveigh ... approved for sale by Health Canada, and Theramed will ...
... June 14, 2011 The U.S. Food and Drug ... hip system for patients with osteoarthritis. ... of bone in the shape of a ball at ... a rounded socket in the pelvis (acetabulum).  During total ...
Cached Medicine Technology:Theramed Corporation to Launch Glenveigh Products, ebb™ and jetty™ at the Society of Obstetricians and Gynecologists of Canada 2FDA Approves First Ceramic-on-Metal Total Hip Replacement System 2
(Date:7/28/2015)... , ... July 28, 2015 , ... ... products, announces Shelled Out, a new household invention that makes shelling eggs an ... billion by 2020,” says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:7/28/2015)... ... ... By 2016, the number of smartphones worldwide will surpass 2 billion. This means that ... increasing customer loyalty. However, capitalizing on this is not always obvious. Companies that do ... competitors. , The Open Mobile Summit 2015 is an influential gathering of mobile visionaries ...
(Date:7/28/2015)... ... July 28, 2015 , ... DuPont leaders today joined public ... learn more about the impact of U.S. collaborations with local partners under the ... agricultural development as an engine of broad-based economic growth in the region. ...
(Date:7/28/2015)... ... 2015 , ... opaJUMP! and O-PA! Performance Academy in ... associated with its training methods. This company is also the first to promise ... in early 2015, training yielded an average 80% improvement in functional health status ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
Breaking Medicine News(10 mins):Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 3Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 4Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 5Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 2Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 6Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 7Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3
... Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, ... Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), has extended ... purchase of all outstanding Ordinary Shares of Taro Pharmaceutical ... at 5:00 p.m., New York City time, on Friday, ...
... finds that for some groups, survival odds after angioplasty ... News) -- A major international study pinpoints which people ... having bypass surgery than artery-opening angioplasty. , "Bypass surgery ... said Dr. Mark Hlatky, professor of health research and ...
... New Definition of ,Bedside Manner,WASHINGTON and RED BANK, N.J., ... (NWHRC) just released the latest issue of its ... Care Reform." The report coincides with the start ... support and awareness of the need for comprehensive health ...
... 20 -- Today, the Migraine Research Foundation (MRF) announced ... pediatric and adolescent migraine called FOR OUR CHILDREN. ... to further the understanding of migraine and its causes ... and adolescents. , Migraine is very common ...
... Message That Pulmonary Fibrosis Can Strike Anyone, Anywhere; Urges Americans ... March 20 Pulmonary Fibrosis (PF) claims a life every ... each year as to breast cancer; yet most Americans have ... someone they love. The Coalition for Pulmonary Fibrosis (CPF) ...
... is that hepatocyte necrosis is the main feature of ... role for hepatocyte apoptosis in this pathogenesis. It is ... in the pathogenesis of fulminant hepatic failure. To ascertain ... the protective effect of a cathepsin B inhibitor (CA-074Me) ...
Cached Medicine News:Health News:Sun Pharmaceutical Extends Tender Offer for Taro 2Health News:Sun Pharmaceutical Extends Tender Offer for Taro 3Health News:Diabetics and Elderly May Fare Better With Bypass 2Health News:Diabetics and Elderly May Fare Better With Bypass 3Health News:National Women's Health Report Addresses Issues of Uninsured Plus New Paradigms of Care 2Health News:New initiative to support pediatric migraine research is announced 2Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 2Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 3
... Healon is a sterile, nonpyrogenic, ... noninflammatory, high molecular weight fraction of ... of sodium hyaluronate dissolved in physiological ... This high molecular weight polymer is ...
... DigitalCameras permit fundus imaging and documentation ... without any need for eyepieces guarantees ... Image recording and display is an ... the ophthalmoscope principle of modern fundus ...
... VISUPAC system and the FF 450plus Fundus ... unique level of accuracy and security that ... aftermarket configuration. Without this level of integrated ... assured.,Matching the VISUPAC system pixel for pixel, ...
... The new Riata i ... even more versatility when ... defibrillation thresholds (DFTs)., The ... family allows physicians even ...
Medicine Products: